Cite
MLA Citation
F. Opdam et al.. “A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations.” European journal of cancer, vol. 174, n.d., pp. S1–. http://access.bl.uk/ark:/81055/vdc_100168600225.0x000044